Merck's antipsychotic Saphris is tied to hypersensitivity, FDA says

09/1/2011 | Medscape (free registration)

Merck & Co.'s atypical antipsychotic Saphris, or asenapine maleate, is associated with serious allergic reactions, including angioedema and anaphylaxis, according to an FDA alert. The agency's Adverse Event Reporting System lists 52 hypersensitivity cases among Saphris users, with some reactions occurring simultaneously or after the first dose.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD